Prevymis (letermovir) - Merck (MSD)
Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis (clinicaltrials.gov) - Aug 5, 2025 - P1 | N=20 | Not yet recruiting | Sponsor: Jason A Roberts 
New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease
http://clinicaltrials.gov/ct2/show/NCT07101055
 
Aug 5, 2025
 
Prev Next